Lobe Sciences to Present At H.C. Wainwright BIOCONNECT Investment Conference Pharmaceutical Investing
Silo Wellness Appoints CEO Douglas K. Gordon to Board of Directors and Provides Corporation Updates Psychedelics Investing
Awakn Life Sciences Expands World's First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral Addictions Psychedelics Investing
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders Psychedelics Investing
COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology Psychedelics Investing
